Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor
Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...
BioSpace23h
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...
How a skin drug trial could help Peninsula biotech pull off key merger
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Fierce Biotech9d
Acelyrin doubles down on Alumis merger after deciding Concentra's surprise offer 'not superior'
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...
BioSpace8d
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage ...
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
The Rights Plan is effective immediately and will expire on March 12, 2026. ACELYRIN stockholders do not need to take any further action at this time.
Acelyrin: Potential Buyout Led By Concentra Biosciences
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
Nasdaq9d
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN ...